MTPConnect Podcast: Learn about the upcoming small-scale manufacturing & training facility at TRI

In the latest episode of the MTPConnect Podcast Series, TRI’s Michelle Richards and Charles Ross from Vaxxas talk about the new TRI Clinical Manufacturing and Training Hub to open later in 2019. 

Supported by the MTPConnect Growth Centre Initiative, the project is a collaboration between TRI and Vaxxas, a technology startup based at TRI specialising in next generation vaccine technology.

The first of its kind in Australia, this hub will assist start-ups and researchers to translate new therapeutics, devices and diagnostics from bench to bedside, by enabling small-scale manufacture of early stage clinical trial products and providing hands-on training to upskill staff and students in pharmaceutical manufacturing.

The facility complies with Good Manufacturing Practice (GMP), with five clean rooms and essential equipment to enable small-scale clinical manufacturing including a state-of-the-art isolator to enable aseptic processing, GMP autoclave and instruments including particle counters, active air samplers and integrity testers. This will enable production of injectables, medical devices, diagnostics, nanoparticle systems, combination drug and device products for use in early stage clinical trials. 

“What we have now is this super flexible, super accessible facility... where people can come in and manufacture their early stage clinical trial product. Staff will be trained up at the facility....then these people can be a pool of staff for commercial entities to use to manufacture their product”, explains Charles Ross, Head of Clinical Operations and Supply at Vaxxas.